Pemetrexed combined with paclitaxel: A dose-finding study evaluating three schedules in solid tumors

Investigational New Drugs

Volumn 27, Issue 4, 2009, Pages 356-365

  Hanauske, Axel R ^a   Dumez, Herlinde ^b   Piccart, Martine ^c   Yilmaz, Emine ^a   Graefe, Tobias ^a   Gil, Thierry ^c   Simms, Lorinda ^d   Musib, Luna ^d   Awada, Ahmad ^c  

^a DEPARTMENT OF CARDIOLOGY   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Combination chemotherapy; Paclitaxel; Pemetrexed; Phase I; Vitamin supplementation

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PEMETREXED; THYROGLOBULIN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APPETITE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CREATININE CLEARANCE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESOPHAGUS CANCER; ESTHESIONEUROBLASTOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHARYNX CARCINOMA; INFECTION; KIDNEY CARCINOMA; LEIOMYOMA; LEUKOPENIA; LIVER CANCER; LUNG CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PANCREAS ADENOCARCINOMA; PAROTID GLAND CARCINOMA; PENIS CARCINOMA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RESPIRATORY FAILURE; SARCOMA; SEPSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VITAMIN SUPPLEMENTATION;

EID: 67651159193     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9193-5     Document Type: Article

References (27)

1. Shih C, Thornton D (1999) Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514). In: Jackman AL (ed) Anti cancer drug development guide: antifolate drugs in cancer therapy. Humana, New Jersey, pp 183-201
2. A-R Hanauske V Chen P Paoletti C Niyikiza 2001 Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors Oncologist 6 363 373 doi:10.1634/theoncologist.6-4-363
3. C Niyikiza SD Baker DE Seitz S Baker D Seitz J Walling 2002 Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy Mol Cancer Ther 1 545 552
4. EK Rowinsky LA Cazenave RC Donehower 1990 Taxol: a novel investigational antineoplastic agent J Natl Cancer Inst 82 1247 1259 doi:10.1093/jnci/82.15.1247 (Pubitemid 20239995)
5. JG Kuhn 1994 Pharmacology and pharmacokinetics of paclitaxel Ann Pharmacother 28 Suppl 5 S15 S17
6. R Pazdur AP Kudelka JJ Kavanagh PR Cohen MN Raber 1993 The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®) Cancer Treat Rev 19 351 386 doi:10.1016/0305-7372(93)90010-O
7. DA Rinaldi JG Kuhn HA Burris FA Dorr G Rodriguez SG Eckhardt 1999 A phase I evaluation of multitargeted antifolate (MTA, LY231514) administered every 21 days, using the modified continual reassessment methods for dose escalation Cancer Chemother Pharmacol 44 372 380 doi:10.1007/s002800050992
8. B Monsarrat P Alvinerie M Wright J Dubois F Guéritte-Voegelein D Guénard 1993 Hepatic metabolism and biliary excretion of Taxol in rats and humans J Natl Cancer Inst Monogr 15 39 46
9. JH Beijnen MT Huizing WW ten Bokkel Huinink CH Veenhof JB Vermorken G Giaccone 1994 Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel Semin Oncol 21 Suppl 8 53 62 (Pubitemid 24322775)
10. L Gianni CM Kearns A Gianni G Capri L Viganó A Lacatelli 1995 Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetics/pharmacodynamics relationship in humans J Clin Oncol 13 180 190
11. T Ohtsu Y Sasaki T Tamura Y Miyata H Nakanomyo Y Nishiwaki 1995 Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion Clin Cancer Res 1 599 606
12. S Green GR Weiss 1992 Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria Invest New Drugs 10 239 253 doi:10.1007/BF00944177
13. L Celio E Bajetta L Toffolatti 2000 Phase II trial of pemetrexed disodium administered every 21 days in patients (pts) with gastric cancer: efficacy and toxicity without and with folic acid Ann Oncol 11 Suppl 4 65 doi:10.1023/A:1008356806417
14. L Hammond M Villalona-Calero SG Eckhardt 1998 A phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid (FA) Ann Oncol 9 620
15. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 doi:10.1159/000130554
16. National Cancer Institute (1993) Common Toxicity Criteria (CTC) scale, version 1
17. JE Latz A Chaudhary A Ghosh RD Johnson 2006 Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients Cancer Chemother Pharmacol 57 401 411 doi:10.1007/s00280-005-0036-1
18. A Hughes P Calvert A Azzabi R Plummer R Johnson J Rusthoven 2002 Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma J Clin Oncol 20 3533 3544 doi:10.1200/JCO.2002.10.073
19. K Nakagawa S Kudoh K Matsui S Negoro N Yamamoto JE Latz 2006 A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours Br J Cancer 95 677 682 doi:10.1038/sj.bjc. 6603321
20. Y Kano M Akutsu S Tsunoda T Izumi K Mori H Fujii 2004 Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro Cancer Chemother Pharmacol 54 505 513 doi:10.1007/s00280- 004-0839-5
21. CH Smorenburg A Sparreboom M Bontenbal J Verweij 2001 Combination chemotherapy of the taxanes and antimetabolites: its use and limitations Eur J Cancer 37 2310 2323 doi:10.1016/S0959-8049(01)00309-4
22. MH Huber JS Lee RA Newman FV Fossella M Wester WK Hong 1996 A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors Ann Oncol 7 59 63 (Pubitemid 26050507)
23. JR Rigas MG Kris VA Miller KM Pisters RT Heelan SC Grant 1999 Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors Ann Oncol 10 601 603 doi:10.1023/A:1026404812699
24. GP Stathopoulos J Dimitroulis M Toubis C Katis D Karaindros J Stathopoulos 2007 Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial Lung Cancer 57 66 71 doi:10.1016/j.lungcan.2007.02.003
25. AC Mita CJ Sweeney SD Baker A Goetz L Hammond A Patnaik 2006 Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function J Clin Oncol 24 552 562 doi:10.1200/JCO.2004.00.9720
26. CM Kearns CP Belani K Erkmen M Zuhowski D Hiponia Zacharski 1995 Pharmacokinetics of paclitaxel and carboplatin in combination Semin Oncol 22 Suppl 12 1 4
27. GN Schwartz L Pendyala H Kindler N Meropol R Perez D Raghavan 1998 The clinical development of paclitaxel and the paclitaxel/carboplatin combination Eur J Cancer 34 1543 1548 doi:10.1016/S0959-8049(98)00225-1